期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

氟维司群是绝经后复发转移性乳腺癌内分泌治疗的新选择 被引量：3

Fulvestrant: A New Choice in the Management of Hormone Receptor-positive Metastatic Breast Cancer in Postmenopausal Women
下载PDF
导出
摘要 氟维司群是一种新型的竞争性、“纯粹的”雌激素受体抗拮剂,具有如下特点：⑴与TAM不同,不具有部分雌激素受体激动作用,和ER高结合力结合后可以阻断ER信号传导通路,
作者 林晓琳 邸立军
机构地区 北京大学肿瘤医院 北京市肿瘤防治研究所乳腺肿瘤内科恶性肿瘤发病机制及转化研究教育部重点实验室
出处 《药品评价》 CAS 2012年第6期7-9,共3页 Drug Evaluation
关键词 乳腺癌 内分泌治疗 氟维司群 Breast cancer Endocrine therapy Fulvestrant
分类号 R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献11

  • 1Howell A,Robertson J F,Quaresma Albano J. Fulvestrant,formerly ICI 182,780,is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment[J].Journal of Clinical Oncology,2002,(16):3396-3403. 被引量：1
  • 2Osborne C K,Pippen J,Jones S E. Double-blind,randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy:results of a North American trial[J].Journal of Clinical Oncology,2002,(16):3386-3395. 被引量：1
  • 3Xu B,Jiang Z,Shao Z. Fulvestrant 250 mg versus anastrozole for Chinese patients with advanced breast cancer:results of a multicentre,double-blind,randomised phase Ⅲ trial[J].Cancer Chemotherapy and Pharmacology,2011,(01):223-230. 被引量：1
  • 4Addo S,Yates R A,Laight A.Yates,A.Laight. A phase Ⅰ trial to assess the pharmacology of the new oestrogen receptor antagonist thlvestrant on the endometrium in healthy postmenopausal volunteers[J].British Journal of Cancer,2002,(12):1354-1359. 被引量：1
  • 5Ohno S,Rai Y,Iwata H. Three dose regimens of fulvestrant in postmenopausal Japanese women with advanced breast cancer:results from a double-blind,phase Ⅱ comparative study (FINDER1)[J].Annals of Oncology,2010,(12):2342-2347. 被引量：1
  • 6Pritchard K I,Rolski J,Papai Z. Results of a phase Ⅱ study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2)[J].Breast Cancer Research and Treatment,2010,(02):453-461. 被引量：1
  • 7Di Leo A,Jerusalem G,Petruzelka L. Results of the CONFIRM phaseⅢtrial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer[J].Journal of Clinical Oncology,2010,(30):4594-4600. 被引量：1
  • 8Robertson J F,Llombart-Cussac A,Rolski J. Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer:results from the FIRST study[J].Journal of Clinical Oncology,2009,(27):4530-4535. 被引量：1
  • 9Mauriac L,Romieu G,Bines J.Romieu,J.Bines. Activity of fulvestrant versus exemestane in advanced breast cancer patients with or without visceral metastases:data from the EFECT trial[J].Breast Cancer Research and Treatment,2009,(01):69-75.doi:10.1007/s10549-008-0141-z. 被引量：1
  • 10Vergote I,Robertson J F,Kleeberg U. Postmenopausal women who progress on fulvestrant (Faslodex') remain sensitive to further endocrine therapy[J].Breast Cancer Research and Treatment,2003,(02):207-211.doi:10.1023/A:1023983032625. 被引量：1

同被引文献52

  • 1王佳玉,袁芃,马飞,樊英,张频,李青,徐兵河.氟维司群治疗绝经后转移性乳腺癌患者的疗效及安全性[J].中国癌症杂志,2011,21(6):461-464. 被引量：9
  • 2SAADATMAND S, TILANUS-LINTHORST M M, RUTGERS E J, et al. Cost-effectiveness of screening women with familial risk for breast cancer with magnetic resonance imaging [ J ] . J Natl Cancer Inst, 2013, 105(17): 1314-1321. 被引量：1
  • 3BUZDAR A U, ROBERTSON J F. Fulvestrant: pharmacologic profile versus existing endocrine agents for the treatment of breast cancer [ J ] . Ann Pharmacother, 2006, 40(9): 1572- 1583. 被引量：1
  • 4OSBORNE C K, WAKELING A, NICHOLSON R I. Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action [ J ] . Br J Cancer, 2004, 90(Suppl 1): 2-6. 被引量：1
  • 5OSBORNE C K, CORONADO-HEINSOHN E B, HILSENBECK S G, et al. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer [ J ] . J Natl Cancer Inst, 1995, 87(10): 746-750. 被引量：1
  • 6KUTER I, GEE J M, HEGG R, et al. Dose-dependent change in biomarkers during neoadjuvant endocrine therapy with fulvestrant: results from NEWEST, a randomized phase Ⅱ study [ J ] . Breast Cancer Res Treat, 2012, 133(1): 237-246. 被引量：1
  • 7DI LEO A, JERUSALEM G, PETRUZELKA L, et al. Results of the CONFIRM phase HI trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer [ J] . J Clin Oncol, 2010, 28(30): 4594-4600. 被引量：1
  • 8HOWELL A, ROBERTSON J F, QUARESMA ALBANO J, et al. Fulvestrant, formerly ICI 182 780 is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment [ J ] . J Clin Oncol, 2002, 20(16): 3396-3403. 被引量：1
  • 9OSBORNE C K, PIPPEN J, JONES S E, et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial [ J ] . J Clin Oncol, 2002, 20(16): 3386-3395. 被引量：1
  • 10XU B, JIANG Z, SHAO Z, et al. Fulvestrant 250 mg versus anastrozole for Chinese patients with advanced breast cancer: results of a multieentre, double-blind, randomised phase m trial [ J ] . Cancer Chemother Pharmacol, 2011, 67(1): 223- 230. 被引量：1

引证文献3

二级引证文献16

药品评价
2012年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部